Article: Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright

Article - Media

Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright

Austin Angelo

AnalystRatings, 1 May 2020

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today and set a price target of $4.00. The company’s shares closed last Thursday at $3.75.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.2% and a 41.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Collegium Pharmaceutical.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

 

Article: Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright

Article - Media

Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright

Austin Angelo

SmarterAnalyst, 30 April 2020

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (), with a price target of $295.00. The company’s shares closed last Wednesday at $251.05.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

Article: H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)

Article - Media

H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)

Austin Angelo

SmarterAnalyst, 30 April 2020

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aravive (ARAV), with a price target of $15.00. The company’s shares closed last Thursday at $12.95.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.